These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18505929)

  • 1. Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
    Nagpal JK; Nair S; Chakravarty D; Rajhans R; Pothana S; Brann DW; Tekmal RR; Vadlamudi RK
    Mol Cancer Res; 2008 May; 6(5):851-61. PubMed ID: 18505929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
    Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
    Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
    Nair BC; Nair SS; Chakravarty D; Challa R; Manavathi B; Yew PR; Kumar R; Tekmal RR; Vadlamudi RK
    Cancer Res; 2010 Sep; 70(18):7166-75. PubMed ID: 20807815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
    Vadlamudi RK; Manavathi B; Balasenthil S; Nair SS; Yang Z; Sahin AA; Kumar R
    Cancer Res; 2005 Sep; 65(17):7724-32. PubMed ID: 16140940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.
    Manavathi B; Nair SS; Wang RA; Kumar R; Vadlamudi RK
    Cancer Res; 2005 Jul; 65(13):5571-7. PubMed ID: 15994929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
    Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
    Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
    Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging significance of ER-coregulator PELP1/MNAR in cancer.
    Nair S; Vadlamudi RK
    Histol Histopathol; 2007 Jan; 22(1):91-6. PubMed ID: 17128415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PELP1/MNAR signaling in ovarian tumorigenesis.
    Dimple C; Nair SS; Rajhans R; Pitcheswara PR; Liu J; Balasenthil S; Le XF; Burow ME; Auersperg N; Tekmal RR; Broaddus RR; Vadlamudi RK
    Cancer Res; 2008 Jun; 68(12):4902-9. PubMed ID: 18559538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
    Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
    Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
    Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
    Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
    Nair SS; Guo Z; Mueller JM; Koochekpour S; Qiu Y; Tekmal RR; Schüle R; Kung HJ; Kumar R; Vadlamudi RK
    Mol Endocrinol; 2007 Mar; 21(3):613-24. PubMed ID: 17192406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
    Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
    Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Stem Cell Phenotypes in ER
    Truong TH; Hu H; Temiz NA; Hagen KM; Girard BJ; Brady NJ; Schwertfeger KL; Lange CA; Ostrander JH
    Mol Cancer Res; 2018 Apr; 16(4):707-719. PubMed ID: 29348189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PELP1 oncogenic functions involve alternative splicing via PRMT6.
    Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
    Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein.
    Balasenthil S; Vadlamudi RK
    J Biol Chem; 2003 Jun; 278(24):22119-27. PubMed ID: 12682072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PELP1: A novel therapeutic target for hormonal cancers.
    Chakravarty D; Tekmal RR; Vadlamudi RK
    IUBMB Life; 2010 Mar; 62(3):162-9. PubMed ID: 20014005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extranuclear coactivator signaling confers insensitivity to tamoxifen.
    Kumar R; Zhang H; Holm C; Vadlamudi RK; Landberg G; Rayala SK
    Clin Cancer Res; 2009 Jun; 15(12):4123-30. PubMed ID: 19470742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains.
    Choi YB; Ko JK; Shin J
    J Biol Chem; 2004 Dec; 279(49):50930-41. PubMed ID: 15456770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
    Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.